SPRY SHAREHOLDER ACTION NOTICE: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026

Faruqi & Faruqi is investigating potential securities claims against ARS Pharmaceuticals (NASDAQ: SPRY) and is reminding investors of an October 5, 2026 deadline to seek lead-plaintiff status in a filed federal securities class action. The notice covers investors who purchased or acquired ARS Pharmaceuticals shares between March 9, 2026 and June 24, 2026. While no financial metrics are provided, the litigation risk is a near-term negative overhang for SPRY.

Analysis

This is a classic small-cap biotech litigation overhang, where the first-order impact is usually not damages but the market’s higher discount rate for disclosure quality, management credibility, and future capital raises. For SPRY, the bigger risk is that plaintiffs’ allegations force investors to re-underwrite commercialization execution or prior guidance assumptions; if that happens, the multiple can compress well before any legal outcome is known.

Near term, the deadline flow can keep the name mechanically pressured for weeks as event-driven funds reduce exposure ahead of uncertainty. Over 1-3 months, the key question is whether the company can keep operating metrics clean enough to prevent the lawsuit from becoming a proxy for a broader fundamental slowdown; if not, the market will start pricing not just legal fees but a higher probability of a secondary offering or discounted financing.

Contrarian view: the street often overestimates the economic hit from securities suits unless there is a genuine restatement, regulatory action, or evidence that prior disclosures masked business deterioration. If this stays as a procedural overhang without new facts, the downside can be self-limiting and a sharp relief rally is possible once headline risk fades; what would falsify the bearish setup is a clean next update, quantified legal reserve, and stabilizing volume/price after the lead-plaintiff window closes.

Key Decisions for Investors

• Do not initiate fresh long exposure in SPRY until after the lead-plaintiff deadline and the next company update; the risk/reward is poor while the market is pricing unknown disclosure risk rather than operating fundamentals.
• If already long SPRY, trim into any bounce and keep only a core position; use a recent swing-low break as the stop because litigation headlines can create air pockets in small-cap biotech names.
• For tactical hedging, short SPRY against a long XBI basket or IBB for 2-6 weeks; this isolates idiosyncratic litigation risk while keeping biotech beta neutral.
• If options liquidity is usable, consider a small SPRY put spread into the event window rather than outright short stock; the thesis is limited downside over weeks, not a structural collapse.